Here, we report the development of a bivalent, spherical Ebola virus like particle VLP vaccine that incorporates glycoproteins GPs from Zaire Ebola virus EBOV and Sudan Ebola virus SUDV and is designed to extend the breadth of immunity beyond EBOV. ...VLP vaccination led to a significant increase in the frequency of Ebola GP specific CD4 and CD8 T cell responses. These results demonstrate that a novel bivalent Ebola VLP vaccine elicits strong humoral and cellular immune responses against pathogenic Ebola viruses and support further evaluation of this approach as a potential addition to Ebola vaccine development efforts.IMPORTANCE Ebola outbreaks result in significant morbidity and mortality in affected countries. ...